Skip to main content
Top
Published in: Dermatology and Therapy 3/2022

Open Access 01-03-2022 | Vulgar Psoriasis | Original Research

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis

Authors: George Gondo, Edward Hadeler, Nicholas Brownstone, Emanual Maverakis, Joseph F. Merola, April W. Armstrong, Tina Bhutani, Stacie J. Bell, Wilson Liao

Published in: Dermatology and Therapy | Issue 3/2022

Login to get access

Abstract

Introduction

Achievement of remission in psoriasis is a key goal for patients and providers, yet definitions of remission may vary. Some treat-to-target initiatives in psoriasis have focused on degree of skin involvement, while others have also incorporated quality of life (QoL) measures. The goal of this study is to identify factors associated with patient-reported psoriasis remission.

Methods

The National Psoriasis Foundation conducted a survey of a random stratified sample of 1570 individuals with psoriatic disease in the USA. The survey contained questions regarding provider diagnosis of psoriasis and/or psoriatic arthritis, as well as comorbid conditions and participant demographics. Psoriasis severity was assessed using the Patient Report of Extent of Psoriasis Involvement (PREPI), a validated self-reported measure of body surface area (BSA). Dermatologic-related quality of life was assessed using the Dermatology Life Quality Index (DLQI). Individuals reporting BSA ≤ 3% were asked if they believed their psoriasis was in remission. Multivariate logistic regression was used to identify factors associated with remission.

Results

Of 930 participants reporting BSA ≤ 3%, 479 (51.7%) believed their psoriasis was in remission, with an average remission duration of 31 months. Of those in remission, 79.1% reported current treatment. Multivariate regression revealed that psoriasis remission was independently associated with female sex, lower BSA, less impairment in the Dermatology Life Quality Index and global QoL, biologic use, and concomitant diagnosis of psoriatic arthritis. There was no association with age, race, body mass index, or number of comorbidities.

Conclusion

Overall, patient perception of psoriasis remission was not solely associated with BSA, but also with sex, quality of life, and treatment type.
Literature
1.
go back to reference Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–36.CrossRef Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–36.CrossRef
2.
go back to reference Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8):e0220868.CrossRef Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8):e0220868.CrossRef
3.
go back to reference Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.CrossRef Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.CrossRef
4.
go back to reference Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.CrossRef Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.CrossRef
5.
go back to reference Grine L, de la Brassinne M, Ghislain P-D, Hillary T, Lambert J, Segaert S, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020;34(4):676–84.CrossRef Grine L, de la Brassinne M, Ghislain P-D, Hillary T, Lambert J, Segaert S, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020;34(4):676–84.CrossRef
6.
go back to reference Dommasch ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity, and responsiveness to change of the patient report of extent of psoriasis involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol. 2010;162(4):835–42.CrossRef Dommasch ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity, and responsiveness to change of the patient report of extent of psoriasis involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol. 2010;162(4):835–42.CrossRef
7.
go back to reference Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRef Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRef
8.
go back to reference Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.PubMed Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.PubMed
9.
go back to reference Murer C, Sgier D, Mettler SK, Guillet C, Maul J-T, Djamei V, et al. Gender differences in psoriasis: a Swiss online psoriasis survey. Arch Dermatol Res. 2021;313(2):89–94.CrossRef Murer C, Sgier D, Mettler SK, Guillet C, Maul J-T, Djamei V, et al. Gender differences in psoriasis: a Swiss online psoriasis survey. Arch Dermatol Res. 2021;313(2):89–94.CrossRef
10.
go back to reference Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012;37(3):84–8.PubMed Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012;37(3):84–8.PubMed
11.
go back to reference Schmid Y, Navarini A, Thomas ZRM, Pfleiderer B, Krähenbühl S, Mueller SM. Sex differences in the pharmacology of itch therapies-a narrative review. Curr Opin Pharmacol. 2019;46:122–42.CrossRef Schmid Y, Navarini A, Thomas ZRM, Pfleiderer B, Krähenbühl S, Mueller SM. Sex differences in the pharmacology of itch therapies-a narrative review. Curr Opin Pharmacol. 2019;46:122–42.CrossRef
12.
go back to reference Stumpf A, Burgmer M, Schneider G, Heuft G, Schmelz M, Phan NQ, et al. Sex differences in itch perception and modulation by distraction–an FMRI pilot study in healthy volunteers. PLoS ONE. 2013;8(11): e79123.CrossRef Stumpf A, Burgmer M, Schneider G, Heuft G, Schmelz M, Phan NQ, et al. Sex differences in itch perception and modulation by distraction–an FMRI pilot study in healthy volunteers. PLoS ONE. 2013;8(11): e79123.CrossRef
13.
go back to reference Sunar I, Ataman S, Nas K, Kilic E, Sargin B, Kasman SA, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283–94.CrossRef Sunar I, Ataman S, Nas K, Kilic E, Sargin B, Kasman SA, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283–94.CrossRef
14.
go back to reference Tillett W, Merola JF, Thaçi D, Holdsworth E, Booth N, Lobosco LS, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617–37.CrossRef Tillett W, Merola JF, Thaçi D, Holdsworth E, Booth N, Lobosco LS, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617–37.CrossRef
Metadata
Title
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis
Authors
George Gondo
Edward Hadeler
Nicholas Brownstone
Emanual Maverakis
Joseph F. Merola
April W. Armstrong
Tina Bhutani
Stacie J. Bell
Wilson Liao
Publication date
01-03-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 3/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00692-3

Other articles of this Issue 3/2022

Dermatology and Therapy 3/2022 Go to the issue